HealthdirectFree Australian health advice you can count on.

( ARTG ) Early Breast Cancer,OGIVRI is indicated for the treatment of HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy., Locally Advanced Breast Cancer,OGIVRI is indicated for the treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant OGIVRI., Metastatic Breast Cancer,OGIVRI ‍‍‍‍‍‍​​​‍​​​​​​is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer., Advanced Gastric Cancer,OGIVRI is indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.